Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.58 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.51 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 2/20 | 0.45 |
| ▸ | ESRRG | P62508 | 2/20 | 0.45 |
| ▸ | MAOA | P21397 | 1/20 | 0.45 |
| ▸ | MITF | O75030 | 1/20 | 0.44 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.43 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20748225 | 0.94 | KCNH2 (0.61) | KCNH2SIGMAR1TAAR1LMNAHTR2A | |
| SCHEMBL10666169 | 0.92 | KCNH2 (0.59) | KCNH2SIGMAR1TAAR1LMNAHTR2A | |
| SCHEMBL716077 | 0.86 | TAAR1 (0.61) | KCNH2SIGMAR1TAAR1HTR2AESRRG | |
| SCHEMBL31573982 | 0.86 | KCNH2 (0.67) | KCNH2SIGMAR1LMNAESRRGMITF | |
| Hydrochloric Acid SCHEMBL14157254 | 0.84 | TAAR1 (0.59) | KCNH2TAAR1HTR2AESRRG | |
| SCHEMBL23393840 | 0.84 | KCNH2 (0.51) | KCNH2SIGMAR1ESRRG | |
| SCHEMBL4949030 | 0.83 | TAAR1 (0.44) | KCNH2SIGMAR1TAAR1HTR2AMAOA | |
| SCHEMBL7456580 | 0.81 | KCNH2 (0.59) | KCNH2SIGMAR1LMNAESRRGGRIA4 | |
| SCHEMBL15125588 | 0.81 | MAOB (0.63) | KCNH2TAAR1HTR2AESRRG | |
| SCHEMBL3678682 | 0.81 | MAOA (0.62) | TAAR1HTR2AMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7803827-B2 | 1-N-amino-2-imidazolidinones and derivatives thereof which are effective as Kv1.5 potassium channel inhibitors providing atrial-selective antiarrhythmic agents; 1-(aminosulfonylamino)-3-[2-(4-methoxyphenyl)ethyl]-4-(3,4-dimethylphenyl)-2-imidazolidinone | WYETH LLC (US) | 2010-09-28 | — | — | US | disclosed |
| CN-101573341-A | Imidazolidinone Kv1.5 potassium channel inhibitors | WYETH CORP (US) | 2009-11-04 | — | — | CN | disclosed |
| EP-2035392-A1 | IMIDAZOLE KV1. 5 POTASSIUM CHANNEL INHIBITORS | Wyeth a Corporation of the State of Delaware (US) | 2009-03-18 | — | — | EP | disclosed |
| US-7504517-B2 | Kv1.5 potassium channel inhibitors | WYETH (US) | 2009-03-17 | — | — | US | disclosed |
| US-20090069342-A1 | KV1.5 POTASSIUM CHANNEL INHIBITORS | WYETH (US) | 2009-03-12 | — | — | US | disclosed |
| US-20070299120-A1 | KV1.5 POTASSIUM CHANNEL INHIBITORS | WYETH (US) | 2007-12-27 | — | — | US | disclosed |
| WO-2007149874-A1 | IMIDAZOLIDINONE KV1.5 POTASSIUM CHANNEL INHIBITORS | WYETH (US) | 2007-12-27 | — | — | WO | disclosed |
| US-20040127492-A1 | Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 | PHARMACIA CORPORATION | 2004-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070299120-A1 | KV1.5 POTASSIUM CHANNEL INHIBITORS | KCNJ2, KCNK5, KCNH2 | KCNH2 3/4885SIGMAR1 4450/4885TAAR1 1446/4885 |
| US-20090069342-A1 | KV1.5 POTASSIUM CHANNEL INHIBITORS | KCNJ2, KCNK5, KCNH2 | KCNH2 3/4885SIGMAR1 4450/4885TAAR1 1446/4885 |
| US-20040127492-A1 | Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 | MKNK2, MAPKAPK2, MAP3K2 | KCNH2 1118/4885SIGMAR1 4084/4885TAAR1 3783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.